I have just received the following from my local support group:
One of the historic money spinners for the US pharmaceutical industry faces a potential new hurdle.
Parents looking to calm their rambunctious children with drugs such as Adderall and Ritalin might have a tougher time getting prescriptions thanks to a newly approved device that lets doctors peer into the brains of adolescents.
The US Food and Drug Administration approved the marketing of a new device on Monday that measures electrical impulses given off by the brain's neurons to determine if a child between the ages of six and 17 has attention-deficit/hyperactivity disorder, or ADHD.
ADHD is one of the most widely diagnosed behavioral disorders in the US and health advocates complain that doctors often diagnose it for behaviour that could be attributed to other problems. The American Psychiatric Association estimates that 9 per cent of US adolescents has ADHD.
The new device is called the Neuropsychiatric EEG-Based Assessment Aid (NEBA) System and is a non-invasive test that record brain wave frequencies to determine if a child has ADHD.
Shares of Shire and Novartis, which manufacture Adderall and Ritalin, respectively, reacted calmly to the announcement.